T-cell activation questions feel “easy” until you miss one because a single molecule (or cell type) was swapped in a distractor. The USMLE loves this topic because it forces you to integrate APCs, MHC, costimulation, cytokines, and clinical immunology (HIV, CTLA-4 blockade, transplant, immunodeficiencies)—and every answer choice is designed to test a specific failure point in the pathway.
Tag: Immunology > Innate & Adaptive Immunity
The Clinical Vignette (Q-bank style)
A 42-year-old man with metastatic melanoma is started on an immune checkpoint inhibitor. Two months later, he develops watery diarrhea and abdominal pain. Colonoscopy shows diffuse mucosal inflammation consistent with colitis. Laboratory studies show no infectious cause. The drug he received most likely enhances T-cell activation by blocking which of the following interactions?
A. B7 on antigen-presenting cells binding CD28 on T cells
B. B7 on antigen-presenting cells binding CTLA-4 on T cells
C. ICAM-1 on antigen-presenting cells binding LFA-1 on T cells
D. IL-2 binding the IL-2 receptor on T cells
E. MHC class II on antigen-presenting cells binding the T-cell receptor
Stepwise Approach: What Is T-cell Activation Supposed to Look Like?
The “3-signal” framework (high yield)
Think of naive T-cell activation as requiring:
-
Signal 1: Antigen recognition
- TCR + CD3 binds peptide-MHC on an APC
- CD4 stabilizes binding to MHC II (helper T cells)
- CD8 stabilizes binding to MHC I (cytotoxic T cells)
-
Signal 2: Costimulation (the exam’s favorite trap)
- APC B7 (CD80/86) binds CD28 on the naive T cell
- Without this, the T cell becomes anergic (functionally unresponsive)
-
Signal 3: Cytokine-driven differentiation and clonal expansion
- IL-2 is the classic T-cell growth factor (autocrine/paracrine)
- Differentiation depends on cytokine milieu (e.g., IL-12 → Th1; IL-4 → Th2; IL-6/TGF-β → Th17)
Checkpoints: the “brakes”
- CTLA-4 (on T cells) binds B7 with higher affinity than CD28 → turns down activation (especially early, in lymph nodes)
- PD-1 (on T cells) binds PD-L1/PD-L2 → turns down activation (often in peripheral tissues/tumor microenvironment)
Correct Answer: B. B7 on APCs binding CTLA-4 on T cells
Checkpoint inhibitors used in melanoma commonly include:
- Ipilimumab = anti-CTLA-4
- Nivolumab/Pembrolizumab = anti-PD-1
- Atezolizumab/Durvalumab/Avelumab = anti-PD-L1
Blocking CTLA-4 removes an inhibitory signal, shifting the balance toward greater T-cell activation. That’s good for tumor killing—but it also increases the risk of immune-related adverse events (irAEs), classically:
- Colitis
- Dermatitis
- Hepatitis
- Endocrinopathies (hypophysitis more associated with CTLA-4 blockade; thyroiditis with PD-1/PD-L1 blockade)
High-yield takeaway:
CTLA-4 is the “off switch” competing with CD28 for B7. Block CTLA-4 → more IL-2, more proliferation, more autoimmunity-like toxicity.
Why Every Distractor Is Wrong (and what it’s trying to test)
A. B7 binding CD28 — Wrong (but important)
This interaction is pro-activation costimulation.
- If you block B7–CD28, you reduce T-cell activation and can induce anergy.
- Classic pharmacology tie-in: Abatacept (CTLA-4–Ig) binds B7, preventing CD28 costimulation → used in RA and transplant-related contexts.
What the test wants: Do you know B7–CD28 = gas pedal, not brake?
C. ICAM-1 binding LFA-1 — Wrong, but tests adhesion vs activation
- LFA-1 (on T cells) binds ICAM-1 (on APCs/endothelium) to stabilize the immunologic synapse and support trafficking.
- This helps cells stick and signal efficiently, but it’s not the key “second signal” like B7–CD28.
Clinchers to remember:
- Leukocyte adhesion deficiency type 1 involves defective CD18 (part of LFA-1) → impaired adhesion/migration, recurrent infections, no pus, delayed separation of umbilical cord.
What the test wants: Don’t confuse “synapse stability” with “costimulation.”
D. IL-2 binding IL-2 receptor — Wrong direction for checkpoint inhibitor mechanism
- IL-2 is a major driver of T-cell proliferation after activation.
- But checkpoint inhibitors work upstream by modulating inhibitory receptor signaling (CTLA-4/PD-1)—not by directly blocking IL-2 signaling.
High-yield related facts:
- Calcineurin inhibitors (cyclosporine, tacrolimus) → ↓ IL-2 transcription (via NFAT inhibition) → ↓ T-cell activation.
- Sirolimus (rapamycin) inhibits mTOR downstream of IL-2 → blocks T-cell proliferation.
What the test wants: Place therapies at the correct “step” in the pathway:
- Calcineurin inhibitors: IL-2 transcription
- Sirolimus: IL-2 response
- Checkpoint inhibitors: release inhibitory receptor brakes
E. MHC II binding TCR — Wrong, tests Signal 1 vs Signal 2
This is Signal 1 (antigen recognition). Blocking it would blunt activation, but it’s not what checkpoint inhibitors do.
USMLE micro-associations:
- Bare lymphocyte syndrome type II (MHC II deficiency) → ↓ CD4 T cells, recurrent pyogenic infections.
- HIV targets CD4 T cells, impairing downstream B-cell class switching and macrophage activation.
What the test wants: Separate:
- Signal 1 = TCR–MHC
- Signal 2 = B7–CD28
- Inhibitory modulation = CTLA-4 / PD-1
Quick Table: Signals, Molecules, and What Happens if You Lose Them
| Step | Key interaction | Where it happens | If absent/blocked | Classic tie-in |
|---|---|---|---|---|
| Signal 1 | TCR (CD3) + peptide–MHC | APC–T cell synapse | No antigen-specific activation | MHC II deficiency, HIV (functional loss of CD4 help) |
| Signal 2 | B7 (CD80/86)–CD28 | Lymph node priming | Anergy | Abatacept blocks this |
| “Brake” | B7–CTLA-4 | Early activation (LN) | More activation, more irAEs | Ipilimumab → colitis, hypophysitis |
| “Brake” | PD-1–PD-L1/2 | Peripheral tissues | More activation, more irAEs | Pembrolizumab/nivolumab |
| Proliferation | IL-2–IL-2R, mTOR | After activation | Less clonal expansion | Cyclosporine/tacrolimus, sirolimus |
High-Yield USMLE Pearls (the stuff that turns 60% into 90%)
1) Anergy is a favorite stem ending
If you see:
- Antigen presentation without costimulation
- Or “absence of B7 expression”
Expect: T-cell anergy (especially in naive T cells).
2) Professional APCs matter
Dendritic cells are the most important for priming naive T cells. Also:
- Macrophages
- B cells (especially for activating helper T cells during humoral responses)
3) Checkpoint inhibitor toxicity = “autoimmunity-like”
When a patient on CTLA-4/PD-1 therapy develops:
- Diarrhea (colitis)
- Cough/dyspnea (pneumonitis)
- Jaundice (hepatitis)
- Fatigue + endocrine changes (thyroid, pituitary) Think: immune-related adverse event.
4) CD40–CD40L is not “T-cell activation,” but it’s adjacent and tested
- CD40L (on Th cells) binds CD40 (on B cells/macrophages)
- Needed for:
- Class switching (B cells)
- Macrophage activation (Th1 help)
- Defect → Hyper-IgM syndrome (class switching failure)
How to “Read” the Answer Choices Like the Test Writer
When the question says “enhances T-cell activation,” immediately scan for:
- Blocking inhibitory signals (CTLA-4, PD-1) → enhances activation
vs - Blocking required activation signals (TCR–MHC, B7–CD28, IL-2) → decreases activation
In this vignette, the colitis after melanoma therapy screams checkpoint inhibitor irAE, and CTLA-4 is the classic association.
Mini Self-Check (1-liners)
- B7–CD28: “Yes, activate.”
- B7–CTLA-4: “No, slow down.”
- PD-1–PD-L1: “No, slow down in tissues.”
- No costimulation: “Anergy.”
- IL-2: “Clone army.”